ID   UTA.00112.hFF
AC   CVCL_RN16
SY   UTA.00112; WTa
DR   Wikidata; Q54992201
RX   PubMed=22052944;
RX   PubMed=22315618;
RX   PubMed=22962621;
RX   PubMed=23119085;
RX   PubMed=23341440;
RX   PubMed=27026928;
CC   From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland.
CC   Population: Caucasian.
CC   Derived from site: In situ; Foreskin, skin; UBERON=UBERON_0001471.
CC   Cell type: Fibroblast of foreskin; CL=CL_1001608.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2769 ! CCD-1112Sk
SX   Male
AG   <1M
CA   Induced pluripotent stem cell
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 7
//
RX   PubMed=22052944; DOI=10.1242/dmm.008409; PMCID=PMC3291643;
RA   Lahti A.L., Kujala V.J., Chapman H., Koivisto A.-P.,
RA   Pekkanen-Mattila M., Kerkela E., Hyttinen J.A.K., Kontula K., Swan H.,
RA   Conklin B.R., Yamanaka S., Silvennoinen O., Aalto-Setala K.;
RT   "Model for long QT syndrome type 2 using human iPS cells demonstrates
RT   arrhythmogenic characteristics in cell culture.";
RL   Dis. Model. Mech. 5:220-230(2012).
//
RX   PubMed=22315618; DOI=10.1155/2012/875059; PMCID=PMC3270482;
RA   Pekkanen-Mattila M., Ojala M., Kerkela E., Rajala K., Skottman H.,
RA   Aalto-Setala K.;
RT   "The effect of human and mouse fibroblast feeder cells on cardiac
RT   differentiation of human pluripotent stem cells.";
RL   Stem Cells Int. 2012:875059.1-875059.10(2012).
//
RX   PubMed=22962621; DOI=10.1371/journal.pone.0044660; PMCID=PMC3433449;
RA   Kujala K., Paavola J., Lahti A.L., Larsson K., Pekkanen-Mattila M.,
RA   Viitasalo M., Lahtinen A.M., Toivonen L., Kontula K., Swan H.,
RA   Laine M., Silvennoinen O., Aalto-Setala K.;
RT   "Cell model of catecholaminergic polymorphic ventricular tachycardia
RT   reveals early and delayed afterdepolarizations.";
RL   PLoS ONE 7:E44660-E44660(2012).
//
RX   PubMed=23119085; DOI=10.1371/journal.pone.0048659; PMCID=PMC3485380;
RA   Ojala M., Rajala K., Pekkanen-Mattila M., Miettinen M., Huhtala H.,
RA   Aalto-Setala K.;
RT   "Culture conditions affect cardiac differentiation potential of human
RT   pluripotent stem cells.";
RL   PLoS ONE 7:E48659-E48659(2012).
//
RX   PubMed=23341440; DOI=10.5966/sctm.2012-0047; PMCID=PMC3659749;
RA   Toivonen S., Ojala M., Hyysalo A., Ilmarinen T., Rajala K.,
RA   Pekkanen-Mattila M., Aanismaa R., Lundin K., Palgi J., Weltner J.,
RA   Trokovic R., Silvennoinen O., Skottman H., Narkilahti S.,
RA   Aalto-Setala K., Otonkoski T.;
RT   "Comparative analysis of targeted differentiation of human induced
RT   pluripotent stem cells (hiPSCs) and human embryonic stem cells reveals
RT   variability associated with incomplete transgene silencing in
RT   retrovirally derived hiPSC lines.";
RL   Stem Cells Transl. Med. 2:83-93(2013).
//
RX   PubMed=27026928; DOI=10.1186/s40064-016-1889-y; PMCID=PMC4771667;
RA   Kuusela J., Kujala V.J., Kiviaho A.L., Ojala M., Swan H., Kontula K.,
RA   Aalto-Setala K.;
RT   "Effects of cardioactive drugs on human induced pluripotent stem cell
RT   derived long QT syndrome cardiomyocytes.";
RL   SpringerPlus 5:234.1-234.13(2016).
//